Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
复制标题
DOI：
10.1159/000452846
复制
发表时间：
2017-01-01
期刊：
影响因子：
13.8
通讯作者：
Michitaka, Kojiro
中科院分区：
文献类型：
--
作者：
Hiraoka, Atsushi;Kumada, Takashi;Michitaka, Kojiro
目的/背景：本研究的目的是评价用于评估肝功能的3种分类的有效性，即肝损伤和Child-Pugh分类以及新提出的白蛋白-胆红素（ALBI）分级，以检查使用ALBI分级和日本使用的肝细胞癌（HCC）治疗算法评估肝功能的可行性。研究方法：我们分析了2000年至2015年收治的3，495名日本HCC患者的病历，其中包括1，580名在爱媛县地区住院的患者，并用作培训队列（爱媛组），以及1，915名用于验证的患者（验证组）。用于分级的ALBI评分（
Aim/Background: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. Methods: We analyzed the medical records of 3,495 Japanese HCC patients admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group). ALBI score used for grading (